Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar pavlos1971 (99.44) Submitted: 2/25/2013 8:06:26 AM : Outperform Start Price: $18.42 DVAX Score: +15.65

FDA didn't approve this morning; company will file again soon for more limited label.

Featured Broker Partners


Advertisement